These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 6696702)

  • 41. Antimotion sickness and antiemetic drugs.
    Wood CD
    Drugs; 1979 Jun; 17(6):471-9. PubMed ID: 467277
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions.
    Wood CD; Graybiel A
    Aerosp Med; 1968 Dec; 39(12):1341-4. PubMed ID: 4881887
    [No Abstract]   [Full Text] [Related]  

  • 43. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults.
    Makris AP; Rush CR; Frederich RC; Taylor AC; Kelly TH
    Exp Clin Psychopharmacol; 2007 Apr; 15(2):123-33. PubMed ID: 17469936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention and treatment of space sickness in shuttle-orbiter missions.
    Graybiel A
    Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NTP Toxicology and Carcinogenesis Studies of Promethazine Hydrochloride (CAS No. 58-33-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Dec; 425():1-272. PubMed ID: 12616286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Theory of antimotion sickness drug mechanisms.
    Wood CD; Graybiel A
    Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925
    [No Abstract]   [Full Text] [Related]  

  • 47. Promethazine affects autonomic cardiovascular mechanisms minimally.
    Brown TE; Eckberg DL
    J Pharmacol Exp Ther; 1997 Aug; 282(2):839-44. PubMed ID: 9262349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Airsickness prevention in helicopter passengers.
    Estrada A; LeDuc PA; Curry IP; Phelps SE; Fuller DR
    Aviat Space Environ Med; 2007 Apr; 78(4):408-13. PubMed ID: 17484344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms underlying the antimotion sickness effects of psychostimulants.
    Kohl RL; Lewis MR
    Aviat Space Environ Med; 1987 Dec; 58(12):1215-8. PubMed ID: 3322253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of a new antinauseant drug for the prevention of motion sickness.
    Graybiel A; Knepton J
    Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
    [No Abstract]   [Full Text] [Related]  

  • 53. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Motion sickness].
    Naess K
    Tidsskr Nor Laegeforen; 1971 Aug; 91(24):1764-5. PubMed ID: 5111147
    [No Abstract]   [Full Text] [Related]  

  • 56. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Motion sickness.
    Lovan WD
    Am Fam Physician; 1984 Jun; 29(6):117-22. PubMed ID: 6731246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of phenytoin in the prevention of motion sickness.
    Chelen W; Kabrisky M; Hatsell C; Morales R; Fix E; Scott M
    Aviat Space Environ Med; 1990 Nov; 61(11):1022-5. PubMed ID: 2256875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.